What Is Galmed Pharmaceuticals Ltd. (GLMD) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Galmed Pharmaceuticals Ltd.'s intrinsic value is estimated at a composite fair value of $0.40. Trading at $0.51, the stock is approaching fair value or slight overvaluation (implied return of -22.6%), as 4 of 6 models suggest limited further upside. Notably, Dynamic NAV sees the most upside at +133.5% (fair value: $1.20), while Sentiment SOTP is the most conservative at -81.2% ($0.10). The spread between these extremes — +214.7% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About GLMD?
6 of 13 models are currently active for GLMD. Of these, 2 models suggest upside while 4 models suggest overvaluation. The Bayesian DCF estimates GLMD's intrinsic value at $0.18, implying -64.3% downside from the current price. See which stocks rank higher →
How Does GLMD Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, GLMD ranks #401 by Quality of Company score. CirclFi's QOC score of 2.3/10 evaluates 32 fundamental signals. A score of 2.3 signals below-average fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Galmed Pharmaceuticals Ltd.'s positioning within the Pharmaceutical Preparations segment means that pipeline depth and stage distribution plays an outsized role in fundamental analysis. The sector's unique characteristics — including licensing and M&A optionality — shape both the opportunity set and risk profile.
Is GLMD a Value Trap?
CirclFi's Value Trap algorithm assigns GLMD a score of 15/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
6 of 13 models are active for Galmed Pharmaceuticals Ltd.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, Galmed Pharmaceuticals Ltd. earns a quality score of 2.3/10. This concerning rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.
The gap between the most bullish and bearish model spans +214.7% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every GLMD valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across GLMD's 6 active models, average confidence is 16%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad